Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2003

Murray SA, Zheng H, Gu L, Xiao Z-. IGF-1 activates p21 to inhibit UV-induced cell death. Oncogene. 2003;22(11):1703-11.

Brenner RM, Slayden OD, Rodgers WH, Critchley HO, Carroll R, Nie XJ, et al. Immunocytochemical assessment of mitotic activity with an antibody to phosphorylated histone H3 in the macaque and human endometrium. Hum Reprod. 2003;18(6):1185-93.

Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003;1(10):707-15.

Nucci MR, Castrillon DH, Bai H, Quade BJ, Ince TA, Genest DR, et al. Biomarkers in diagnostic obstetric and gynecologic pathology: a review. Adv Anat Pathol. 2003;10(2):55-68.

Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2003:497-519.

Magro CM, Ross P, Kelsey M, W Waldman J, Pope-Harman A. Association of humoral immunity and bronchiolitis obliterans syndrome. Am J Transplant. 2003;3(9):1155-66.

2002

Chiu A, Pan L, Li Z, Ely S, Chadburn A, Knowles DM. DNA polymerase mu gene expression in B-cell non-Hodgkin's lymphomas: an analysis utilizing in situ hybridization. Am J Pathol. 2002;161(4):1349-55.

Winter WE, Kucera PR, Rodgers W, McBroom JW, Olsen C, G Maxwell L. Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol. 2002;100(4):671-6.

Sellers WR, Loda M. The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? Cancer Cell. 2002;2(5):349-50.

Hanash SM, Bobek MP, Rickman DS, Williams T, Rouillard JM, Kuick R, et al. Integrating cancer genomics and proteomics in the post-genome era. Proteomics. 2002;2(1):69-75.